BS_5CTVXVRX
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 32.55584756898817
- age_years
- 10.452
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.699
- MYC_TARGETS_V2+0.649
- E2F_TARGETS+0.642
- OXIDATIVE_PHOSPHORYLATION+0.588
- G2M_CHECKPOINT+0.560
- ALLOGRAFT_REJECTION+0.414
- UNFOLDED_PROTEIN_RESPONSE+0.411
- DNA_REPAIR+0.409
- MTORC1_SIGNALING+0.401
- IL6_JAK_STAT3_SIGNALING+0.347
Top 10 suppressed
- NOTCH_SIGNALING-0.402
- HEDGEHOG_SIGNALING-0.396
- MYOGENESIS-0.344
- WNT_BETA_CATENIN_SIGNALING-0.315
- KRAS_SIGNALING_DN-0.301
- PANCREAS_BETA_CELLS-0.173
- ESTROGEN_RESPONSE_EARLY-0.139
- UV_RESPONSE_DN-0.116
- TGF_BETA_SIGNALING-0.091
- CHOLESTEROL_HOMEOSTASIS-0.065
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-38-4625-01A-01R-1206-07 | — | cohortA1 | 0.893 |
| 2 | BS_3BDAG9YN | medulloblastoma | — | 0.885 |
| 3 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.882 |
| 4 | 1e0f16e6-de1c-4d1e-b1f6-5fabbea1591b | — | — | 0.876 |
| 5 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.874 |
| 6 | SRR6013495 | — | cohortA1 | 0.871 |
| 7 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.869 |
| 8 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.868 |
| 9 | MNG767 | — | — | 0.858 |
| 10 | X11368e6c.aeb6.4de4.8e74.436b1cd1846c | — | cohortA1 | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.699 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.649 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.642 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.588 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.414 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.411 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.409 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.401 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.347 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.311 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.281 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.267 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.256 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.211 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.198 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.187 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.155 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.146 | Idelalisib | — uncovered |